Neuromyelitis optica: An overview

Postgraduate Medical Journal

Volumn 86, Issue 1013, 2010, Pages 153-159

  Nandhagopal, R ^a   Al Asmi, Abdullah ^a   Gujjar, Arunodaya R ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOPATHOLOGY; MYELOOPTIC NEUROPATHY; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; RELAPSE; REVIEW; SEX DIFFERENCE; SPINAL CORD LESION; SPINE RADIOGRAPHY;

AQUAPORIN 4; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROMYELITIS OPTICA; PROGNOSIS;

EID: 77949731621     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.091389     Document Type: Review

References (68)

1. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.
3. Pirko I, Blauwet LK, Lesnick TG, et al. The natural history of recurrent optic neuritis. Arch Neurol 2004;61:1401-5.
4. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007;114:810-15.
5. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507- 14.
6. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256:35-44.
7. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-27.
8. Weinshenker BG, Wingerchuk DM, Nakashima I, et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006;5:110-11.
9. Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci 2008;1142:58-71.
10. Baudoin D, Gambarelli D, Gayraud D, et al. Devic's neuromyelitis optica: a clinicopathological review of the literature in connection with a case showing fatal dysautonomia. Clin Neuropathol 1998;17:175-83.
11. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-6.
12. Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 2008;118:218-25.
13. Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler 2008;14:248-51.
14. Cabrera-Gomez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler 2007;13:186-92.
15. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
16. Blanc F, Zephir H, Lebrun C, et al. Cognitive functions in neuromyelitis optica. Arch Neurol 2008;65:84-8.
17. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79:1075-8.
18. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-82.
19. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009;256:287-8.
20. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11:617-21.
21. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-17.
22. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009;80:679-82.
23. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255:163-70.
24. Okai AF, Muppidi S, Bagla R, et al. Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res 2006;28:354-9.
25. de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008;65:920-3.
26. Merle H, Olindo S, Donnio A, et al. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 2008;49:4412-17.
27. Yu CS, Lin FC, Li KC, et al. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 2006;27:1009-15.
28. Rocca MA, Agosta F, Mezzapesa DM, et al. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 2004;62:476-8.
29. Yu C, Lin F, Li K, et al. Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging. Radiology 2008;246:222-8.
30. Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004;10:2-4.
31. de Seze J, Lebrun C, Stojkovic T, et al. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003;9:521-5.
32. Zaffaroni M. Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci 2004;25(Suppl 4):S368-70.
33. Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillary acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575-7.
34. Miyazawa I, Nakashima I, Petzold A, et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007;68:865-7.
35. Mandler RN, Dencoff JD, Midani F, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 2001;124(Pt 3):493-8.
36. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-7.
37. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
38. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-8.
39. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008;15:99-105.
40. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130(Pt 5):1235-43.
41. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007;4:e133.
42. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008;196:181-7.
43. Marnetto F, Hellias B, Granieri L, et al. Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol 2009;217:74-9.
44. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
45. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131(Pt 11):3072-80.
46. Weinstock-Guttman B, Miller C, Yeh E, et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 2008;14:1061-7.
47. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(Pt 7):1450-61.
48. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(Pt 5):1194-205.
49. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130(Pt 5):1224-34.
50. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009;386:623-7.
51. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730-7.
52. Zephir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 2009;15:571-9.
53. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848-53.
54. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-5.
55. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-9.
56. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-200.
57. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007;28:209-11.
58. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
59. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65: 1443-8.
60. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51: 1219-20.
61. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-9.
62. Jacobi C, Stingele K, Kretz R, et al. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. Lupus 2006;15: 107-9.
63. Gibbs AN, Moroney J, Foley-Nolan D, et al. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford) 2002;41:470-1.
64. Javed A, Balabanov R, Arnason BG, et al. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 2008;14:809-14.
65. Jacob S, Zarei M, Kenton A, et al. Gluten sensitivity and neuromyelitis optica: two case reports. J Neurol Neurosurg Psychiatry 2005;76:1028-30.
66. Furukawa Y, Yoshikawa H, Yachie A, et al. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 2006;13:655-8.
67. Wilcox RA, Burrow J, Slee M, et al. Neuromyelitis optica (Devic's disease) in a patient with syphilis. Mult Scler 2008;14:268-71.
68. Miranda de Sousa A, Puccioni-Sohler M, Dias Borges A, et al. Post-dengue neuromyelitis optica: case report of a Japanese-descendent Brazilian child. J Infect Chemother 2006;12:396-8.